A Guide to Shingles Vaccination in Australia

A Guide to Shingles Vaccination in Australia

Authored by Dr Aifric Boylan on 21.05.2024
Medically Reviewed by Dr Ali Zavery
Last updated on 11.06.2024

Herpes zoster, known as shingles, is caused by the reactivation of the varicella-zoster virus, the same virus responsible for chickenpox. In Australia, significant strides have been made in preventing this painful condition through effective vaccination strategies.

Understanding shingles

Shingles typically presents as a painful rash that may blister and can appear anywhere on the body but often forms a single stripe on either side of the torso. It is caused by the reactivation of the varicella-zoster virus in individuals who have recovered from chickenpox. Risk factors for developing shingles include age, weakened immunity, and physical or emotional stress.

In response to the increased risk of shingles and its complications among older adults and immunocompromised individuals, the Australian National Immunisation Program (NIP) recommends vaccination in certain groups of people:

Shingrix Vaccine:

  • For Immunocompetent Adults: Adults aged 50 years and older are recommended to receive two doses of Shingrix, 2 to 6 months apart.
  • For Immunocompromised Adults: Those aged 18 years and above should receive two doses at a 1 to 2-month interval.
  • Shingrix is provided free under the NIP for all adults aged 65 years, Aboriginal and Torres Strait Islander people aged 50 years and above, and selected groups aged 18 years and above with severe immunocompromise.

Zostavax Vaccine:

  • A single dose is recommended for immunocompetent adults aged 50 years and over.
  • Zostavax is contraindicated for individuals with severe immunocompromise and is no longer used under the NIP due to its live attenuated nature and the availability of Shingrix.
Book a GP appointment

Why vaccination is critical

The lifetime risk of developing shingles for individuals living to 80 years is approximately 50%. Immunocompromised individuals face even higher risks and more severe complications. Vaccination significantly reduces the incidence of shingles and its most common complication, postherpetic neuralgia, a chronic pain condition that can persist after the rash resolves.

Shingrix: The preferred vaccine

  • Effectiveness: Shingrix has shown over 90% effectiveness in preventing shingles and postherpetic neuralgia. It remains effective across all age groups and for several years post-vaccination.
  • Administration: Shingrix is administered via intramuscular injection, typically in the deltoid muscle. The interval between the first and second doses can be extended beyond 6 months without affecting vaccine efficacy.

Zostavax: Usage considerations

  • Administration: Zostavax is administered as a single 0.65 mL dose by subcutaneous injection.
  • Co-administration with other vaccines: Zostavax can be administered with other inactivated vaccines on the same day or at any time apart. However, live vaccines should be administered at least 4 weeks apart.
picture of shingles rash on patient's torso

Sign up to Qoctor

Precautions and contraindications

  • Individuals who have experienced anaphylaxis due to vaccine components or a previous dose of Shingrix or Zostavax should not receive these vaccines.
  • Zostavax is not recommended for people who are immunocompromised or shortly expected to be due to the risk of disseminated VZV infection.

Supporting Resources

Shingles vaccination is a critical health measure for eligible Australians, particularly given the severe potential complications of the disease. With the availability of effective vaccines like Shingrix, individuals can significantly reduce their risk of developing shingles and experiencing long-term pain. Australians are encouraged to discuss their vaccination options with healthcare providers to ensure optimal protection against this painful condition.

Book a GP appointment

Share This Story, Choose Your Platform!

5 stars
4.6 out of 5
reviewed by Trustpilot

Title